The 13 analysts offering 12-month price forecasts for Iovance Biotherapeutics Inc have a median target of 38.00, with a high estimate of 83.00 and a low estimate of 18.00. The median estimate represents a +64.86% increase from the last price of 23.05.
The current consensus among 14 polled investment analysts is to Buy stock in Iovance Biotherapeutics Inc. This rating has held steady since June, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.51
Reporting Date Aug 06
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.